NanoViricides Highlights Need for Broad-Spectrum Antivirals Amid Influenza Surge

NanoViricides, Inc., a leading company in antiviral drug development, underscores the necessity of broad-spectrum antivirals as a severe influenza wave hits. The current flu season, marked by a novel Influenza A/H3N2 strain, has resulted in millions of illnesses and thousands of deaths, according to the CDC.

Traditional flu vaccines have proved less effective due to mismatches with evolving virus strains. Current antiviral treatments, such as Tamiflu and Xofluza, face challenges of rapid resistance development. In contrast, NanoViricides' NV-387 offers a promising solution, utilizing heparan sulfate to avoid viral escape by mimicking vital virus-binding features.

NV-387 shows potential not only against Influenza but also against RSV and Coronaviruses, aiming to address a multi-billion dollar market. Clinical trials are in progress to evaluate NV-387 as a first-line therapy for respiratory viral infections without the need for specific viral testing.